Defining and Characterizing Drivers of Lethal Metastatic Prostate Cancer
Defining and Characterizing Drivers of Lethal Metastatic Prostate Cancer
批准号:
10579377
负责人:
Grinu Mathew
金额:
$36.88万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-03-01 至 2023-07-19
关键词:
3-DimensionalAffectBehaviorBiochemicalBiological AssayBiologyCRISPR/Cas technologyCancer EtiologyCancer PatientCell Culture TechniquesCell TransplantationCellsCellular biologyCessation of lifeDataData SetDependenceDevelopmentDiseaseDistantEpithelialEventFRAP1 geneFibronectinsGenesGeneticGenomic approachGenotypeGoalsGrowthHumanIndolentInjectionsLesionLigand Binding DomainMaintenanceMalignant NeoplasmsMalignant neoplasm of prostateMetastatic Prostate CancerMetastatic toMigration AssayModelingMolecular TargetNebraskaNeoplasm MetastasisNuclearOrganOrganoidsPTEN genePathway interactionsPhenotypePhosphotransferasesPrimary NeoplasmProstaticReceptor SignalingResearchRoleSignal TransductionSiteTP53 geneTestingTissuesTransplantationTropismTumor Cell LineUp-RegulationWorkaddictionbasecancer cellcell motilityclinical effectclinically relevanteffective therapyepithelial to mesenchymal transitionfunctional genomicsgene functiongenome-widehuman modelin vivoin vivo Modelinhibitorinsightmouse geneticsmouse modelmutantnovelpreventprostate cancer cellprostate cancer metastasisreceptorrecruittooltraittranscriptome sequencingtranslational oncologytransplant model
中文摘要
前列腺癌(PC)是美国癌症相关死亡的第二大原因。我们的目标是
拟议的研究是确定从惰性到致命性转变所必需的遗传因素。
转移性前列腺癌。我们已经从RapidCaP的肿瘤和转移中建立了原代细胞系
致死性PC小鼠模型(PTEN和TP53缺失)。我们的初步数据突显了一个根本性的转变
与转移相关的细胞表型和生长信号。最重要的是,
激酶受体的缺失是这一肿瘤转移相关细胞重编程事件的关键。这些
离散的蜂窝状态与不同的信令行为相关联,这启用或限制
癌细胞的转移潜能。因此,我们现在的重点是描绘激酶在PC中的作用
肿瘤转移及控制原发灶向远处转移转移的信号级联反应
活着。在这项建议中,我们将从机械上验证受体在PC细胞谱系中的作用
重新编程和维持转移性EMT样表型(目标1和3)。接下来,我们将评估
PI3K/mTOR信号轴在缺乏型PC中的作用(目标2)。为落实建议的目标,我们会
与受体信号和前列腺癌疾病生物学方面的专家密切合作。我们的背景
在小鼠遗传学中,细胞生物学和翻译肿瘤学与所需的专业知识很好地结合在一起
并揭开致命转移性PC细胞的遗传依赖性。
英文摘要
Prostate cancer (PC) is the second leading cause of cancer-related deaths in the USA. The goal of our
proposed research is to identify genetic factors that are essential for the switch from indolent to lethal
metastatic prostate cancer. We have generated primary cell lines from tumor and metastasis of the RapidCaP
mouse model for lethal PC (PTEN and TP53 deficient). Our preliminary data highlights a fundamental shift
in cellular phenotype and growth signaling associated with the transition to metastasis. Most importantly, the
loss of TAM kinase receptor is key for this metastasis associated cellular reprogramming event. These
discrete cellular states are associated with divergent signaling behavior, which enables or restricts the
metastatic potential of cancer cells. Therefore, our focus is now on delineating the role of TAM kinases in PC
metastasis and the signaling cascade controlling the switch from primary to distant metastatic disease in
vivo. In this proposal we will mechanistically validate the role of TAM receptors in PC cellular lineage
reprogramming and maintenance of pro-metastatic EMT-like phenotype (Aims 1 and 3). Next, we will assess
the role of PI3K/mTOR signaling axis in TAM-deficient PC (Aim 2). To execute the proposed aims, we will
closely collaborate with experts in receptor signaling and prostate cancer disease biology. Our background
in mouse genetics, cell biology and translational oncology is well aligned with the expertise required to carry
out the proposed work and unravel the genetic dependencies of lethal metastatic PC cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Leveraging PMN immune response to overcome ADT resistance in bone metastatic prostate cancer
-
批准号:10684116
-
项目类别:
-
资助金额:$34.41万
-
财政年份:2022
-
负责人:Grinu Mathew
-
依托单位:
Defining and Characterizing Drivers of Lethal Metastatic Prostate Cancer
-
批准号:10714242
-
项目类别:
-
资助金额:$28.09万
-
财政年份:2018
-
负责人:Grinu Mathew
-
依托单位:
海外基金